In a strategic move aimed at refining its medical technology holdings, Johnson & Johnson has finalized the divestiture of its Laminar left atrial appendage (LAA) closure business to Jaguar LAA, a newly formed entity established in partnership with the investment firm Santé Ventures and members of the original Laminar management team. The transaction represents a significant pivot for the healthcare giant, which only recently acquired the Laminar technology to bolster its position in the high-stakes structural heart market. This divestiture signals a broader shift in Johnson & Johnson MedTech’s strategy as it prioritizes high-growth segments such as interventional cardiology, robotic surgery, and vision care while shedding assets that may not align with its immediate long-term clinical or financial trajectory.
The Laminar technology, which entered the Johnson & Johnson portfolio in late 2023, is designed to address a critical need in the treatment of patients with atrial fibrillation (AFib). AFib is a common heart rhythm disorder that significantly increases the risk of stroke. The left atrial appendage, a small pouch-like structure in the muscle wall of the left atrium, is a primary site for blood clot formation in AFib patients. Traditional treatments involve oral anticoagulants, but for patients who cannot tolerate long-term blood thinners, mechanical LAA closure has emerged as a gold-standard alternative.
The Evolution of the Laminar Acquisition and Divestiture
Johnson & Johnson originally acquired Laminar in November 2023 for an upfront payment of $400 million, with additional milestone payments contingent on regulatory and clinical successes. At the time, the acquisition was viewed as a direct challenge to market leaders Boston Scientific and Abbott Laboratories. Boston Scientific’s Watchman device and Abbott’s Amulet have long dominated the LAA closure landscape, a market estimated to be worth billions of dollars annually.
Following the acquisition, Johnson & Johnson MedTech integrated the technology into its Biosense Webster business, a leader in electrophysiology. In February 2024, the company initiated an investigational device exemption (IDE) study to evaluate the safety and efficacy of the Laminar device compared to the Watchman and Amulet devices. The study was intended to provide the robust clinical data required for U.S. Food and Drug Administration (FDA) approval.
However, the decision to sell the asset less than a year after its acquisition suggests a recalibration of internal priorities. A spokesperson for Johnson & Johnson characterized the sale as a "disciplined approach to portfolio management." By divesting the Laminar program, Johnson & Johnson aims to focus its resources on areas where it can achieve the greatest immediate impact, while allowing the Laminar technology to thrive under a dedicated ownership structure that is exclusively focused on its development and commercialization.
Technical Innovation: How Laminar Differs from Competitors
The LAA closure market has historically been defined by "plug" or "umbrella" style devices. Boston Scientific’s Watchman, for instance, is a self-expanding nitinol frame covered with a permeable fabric that is placed at the opening of the LAA to prevent clots from escaping. While highly effective, these devices leave a foreign body surface area exposed to the blood flow within the left atrium, which requires a period of post-procedural anticoagulation until the device is "endothelialized" (covered by the body’s own tissue).
The Laminar technology offers a differentiated mechanical approach. Rather than simply plugging the appendage, the Laminar device uses a rotational motion to exclude the LAA from the heart’s circulation. According to Jaguar LAA’s Chief Medical Officer, Jason Rogers, the technology is designed to minimize the amount of device hardware exposed to the blood within the left atrium. By reducing the foreign material footprint, the device potentially lowers the risk of device-related thrombus (clot formation on the device itself), which remains a concern with traditional LAA occluders.
This "minimal exposure" philosophy is central to the value proposition of the Laminar program. For clinicians, a device that effectively closes the LAA while promoting faster and cleaner healing could represent a significant leap forward in stroke prevention for AFib patients.
The Prevalence of Atrial Fibrillation and the Stroke Risk
To understand the market importance of the Laminar divestiture, one must look at the staggering clinical data surrounding AFib. According to the Centers for Disease Control and Prevention (CDC), AFib affects an estimated 12.1 million people in the United States alone, with that number expected to rise as the population ages.
Patients with AFib are five times more likely to suffer a stroke than those without the condition. Furthermore, AFib-related strokes tend to be more severe and have a higher rate of mortality and long-term disability compared to strokes from other causes. Because more than 90% of stroke-causing clots in patients with non-valvular AFib originate in the left atrial appendage, the ability to safely and permanently close this structure is a cornerstone of modern cardiovascular care.
The LAA closure market has seen double-digit growth over the last five years. As clinical trials continue to show that mechanical closure is non-inferior to long-term warfarin or direct oral anticoagulant (DOAC) therapy, more patients and physicians are opting for the procedure. This growth has created an environment where even incremental improvements in device design—such as those promised by Laminar—can command significant market share.
Strategic Realignment at Johnson & Johnson MedTech
The sale of Laminar is part of a much larger transformation occurring within Johnson & Johnson’s MedTech division. Under the leadership of Tim Schmid, the executive vice president and worldwide chairman of MedTech, the company has been aggressively reshaping its portfolio to focus on high-growth, high-margin categories.
In recent years, Johnson & Johnson has executed several multi-billion dollar acquisitions to cement its status in the cardiovascular space. These include the $16.6 billion acquisition of Abiomed, the maker of Impella heart pumps, and the $13.1 billion acquisition of Shockwave Medical, a leader in intravascular lithotripsy (IVL) for treating calcified plaque in arteries. These moves indicate that J&J is doubling down on "interventional" solutions that address heart failure and complex coronary artery disease.
Simultaneously, the company is moving toward a leaner operational model. J&J has previously announced plans to spin out or restructure its orthopedics business, a sector that has faced pricing pressures and slower growth compared to the cardiovascular and robotic surgery segments. The divestiture of Laminar, while smaller in scale than an entire business unit spin-off, follows the same logic: shedding assets that require long-term, intensive R&D cycles if they do not fit the immediate "category leadership" goals of the parent organization.
Jaguar LAA and the Path Forward
The buyer, Jaguar LAA, enters the scene with a unique advantage. Because the company includes members of the original Laminar management team, there is significant continuity in the program’s technical and clinical knowledge. Partnering with Santé Ventures, a healthcare-focused venture capital firm with a history of scaling medical device startups, provides the necessary capital to push the device through the remaining regulatory hurdles.
Santé Ventures has built a reputation for identifying "disruptive" medical technologies that solve unmet needs. By taking Laminar out of the massive corporate structure of Johnson & Johnson, Jaguar LAA may be able to operate with greater agility. The primary challenge for the new entity will be the completion of the IDE study and the subsequent submission for FDA Premarket Approval (PMA).
While a spokesperson for Santé Ventures has not yet confirmed if a new clinical trial design is in the works, the industry expectation is that Jaguar LAA will build upon the foundational data already gathered during J&J’s brief tenure. The goal remains to prove that the rotational closure method is not only safe but offers a distinct clinical benefit over the "plug" designs used by Boston Scientific and Abbott.
Competitive Landscape and Market Implications
The LAA closure market is currently a duopoly in the United States, dominated by Boston Scientific and Abbott. Boston Scientific’s Watchman FLX is the market leader, supported by a decade of clinical data and a massive sales force. Abbott’s Amulet has gained ground by offering a "dual-seal" design that some physicians prefer for complex LAA anatomies.
For Jaguar LAA to succeed, it must navigate a landscape where these two giants have already established deep relationships with hospital systems and interventional cardiologists. However, the medical community is often eager for innovation, particularly in "structural heart" procedures where anatomical variability is high. If Jaguar can demonstrate that its minimal-exposure design leads to fewer complications—such as peridevice leaks or thrombus formation—it could find a lucrative niche or even become an acquisition target for another medtech major looking to enter the space, such as Medtronic or Edwards Lifesciences.
Conclusion and Future Outlook
The divestiture of the Laminar LAA closure technology reflects the modern reality of the medical device industry: a focus on "active portfolio management" over mere accumulation of assets. For Johnson & Johnson, the move allows for a sharpened focus on its multi-billion dollar bets in heart failure and vascular intervention. For the Laminar technology, the transition to Jaguar LAA and Santé Ventures may provide the dedicated focus and specialized environment necessary to bring a novel stroke-prevention tool to the global market.
As the clinical trials progress under this new leadership, the cardiovascular community will be watching closely. The success or failure of the Laminar device will not only impact the financial returns for its new owners but will also determine if the next generation of LAA closure technology moves away from traditional plugs toward more biologically integrated, rotational solutions. In the high-stakes world of stroke prevention, even small innovations in how we "close the gap" in the heart can save thousands of lives.
